Medications and Supplements in hEDS

See below for Medication Metabolization and Low-Dose Naltrexone

Hypermobile Ehlers-Danlos syndrome (hEDS) is a complex, multisystem connective tissue disorder with no disease-modifying treatment currently available. Management is highly individualized and relies on symptom control through a combination of medications, supplements, and nonpharmacologic strategies. This article synthesizes current clinical guidance, emerging therapies, and theoretical considerations across the full spectrum of hEDS and its common comorbidities, including postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), gastrointestinal dysmotility (abnormal movement of the digestive tract), psychiatric comorbidities, and nutritional deficiencies. It covers both acute and long-term issues across all age groups, with an emphasis on symptom-specific treatments, careful risk–benefit assessment, and the reality that many medications in hEDS provide partial or situational relief rather than comprehensive symptom control.

Overview of Medication Use in hEDS

While there is no one-size-fits-all treatment, understanding the types of medications and supplements commonly used can help patients and providers build a safer, more effective plan. Medications are typically selected to reduce symptom burden and improve function. A multidisciplinary, symptom-targeted strategy is essential.

• Pain management includes acetaminophen, NSAIDs (used cautiously), SNRIs, anticonvulsants, and occasionally opioids.

• Fatigue and cognitive dysfunction are addressed with supportive care and off-label agents such as low-dose naltrexone.

• Psychiatric comorbidities (especially anxiety and depression) are commonly treated with SSRIs, SNRIs, or tricyclic antidepressants.

• GI issues require a combination of standard agents, prokinetics, reflux treatments, and dietary strategies.

• Supplements support correction of common deficiencies, especially when malabsorption is present.

• POTS and MCAS require dedicated pharmacologic strategies and often interact with the broader hEDS medication plan.

Regular medication review, consideration of route and formulation, and attention to age- and tissue-specific vulnerabilities are all necessary to reduce harm and maximize benefit.

Medications by Symptom Domain

Pain

Chronic pain is often the first and most persistent concern in hEDS. A multimodal approach using pharmacologic and nonpharmacologic interventions is best. Pain in hEDS is often multifactorial—nociceptive, neuropathic, and centrally sensitized—and typically responds poorly to simple analgesics alone.

• First-line agents: Acetaminophen, NSAIDs (or COX-2 inhibitors, used cautiously due to gastrointestinal and bleeding risks). Nonsteroidal anti-inflammatory drugs (NSAIDs) may be helpful when pain has an inflammatory component, such as acute joint irritation, soft-tissue overuse, or injury-related flares. Their role in hypermobile Ehlers-Danlos syndrome is typically limited and requires caution due to connective tissue fragility and frequent gastrointestinal and bleeding vulnerabilities.

  • Over-the-counter (OTC) NSAIDs

    • Examples include ibuprofen and naproxen.

    • Often used intermittently for short-term flares rather than on a daily basis.

    • Even at OTC doses, risks include gastritis, gastrointestinal bleeding, bruising, and kidney stress.

    • OTC availability does not imply safety for chronic or unsupervised use in hEDS.

  • Prescription NSAIDs

    • Include higher-dose and longer-acting formulations.

    • Carry increased risks of gastrointestinal bleeding, cardiovascular effects, and renal injury.

    • Generally avoided as long-term daily therapy in hEDS and used with close monitoring when considered.

  • COX-2 selective inhibitors

    • May reduce gastrointestinal bleeding risk compared with nonselective NSAIDs.

    • Still carry cardiovascular and renal risks and should be used cautiously.

  • Topical NSAIDs

    • May provide localized relief with lower systemic exposure.

    • Can be considered for focal joint or soft-tissue pain when oral NSAIDs are poorly tolerated.

    • Skin fragility and sensitivity should be considered.

  NSAIDs are generally not effective for centrally mediated pain and do not address joint instability, neuropathic pain, or pain amplification.

• Neuropathic pain: SNRIs (e.g., duloxetine), TCAs, gabapentin, pregabalin

• Muscle relaxants

  Muscle overuse, guarding, and spasm commonly contribute to pain in hypermobile Ehlers-Danlos syndrome, particularly as a secondary response to joint instability. Skeletal muscle relaxants are sometimes used as adjunctive therapies, most often short-term or at low doses.

  • Commonly used agents

    • Cyclobenzaprine

    • Tizanidine

    • Baclofen

    • Methocarbamol

  • Situations where they are sometimes used

    • Reduction of painful muscle spasm or guarding

    • Short-term symptom relief during acute flares

    • Nighttime use when muscle-driven pain interferes with sleep

  • Risks and limitations

    • Sedation, dizziness, and cognitive slowing

    • Worsening fatigue or orthostatic symptoms

    • Increased fall risk, particularly in people with dysautonomia

    • Limited evidence for long-term benefit in chronic pain

  Muscle relaxants do not correct joint instability and are not disease-modifying. Regular reassessment is important, and prolonged daily use is generally avoided. It is important to distinguish skeletal muscle relaxants used for musculoskeletal pain from antispasmodic medications used for gastrointestinal symptoms. Although both may reduce cramping or discomfort, they act on different tissues and are used for different indications.

• Refractory (resistant to treatment) cases: Long-acting opioids, tramadol (short term), topical lidocaine, topical capsaicin

• Buprenorphine (partial opioid agonist)

  Buprenorphine is a type of opioid medication with unique properties that sometimes lead clinicians to consider it differently from traditional opioids in chronic pain management. It differs pharmacologically from full opioid agonists by activating opioid receptors more gently, which may lower some risks, and may be considered in carefully selected cases.

  • Formulations

    • Transdermal patches

    • Buccal or sublingual formulations

  • Potential theoretical advantages

    • Ceiling effect on respiratory depression

    • Lower histamine release compared with some full opioid agonists

    • Reduced risk of opioid-induced hyperalgesia relative to long-acting full agonists

  • Limitations and cautions

    • Still carries opioid-related risks, including dependence and tolerance

    • May interact with other sedating medications

    • Can complicate future pain management if additional opioids are required

    • Not well studied specifically in hEDS

  Buprenorphine is not a first-line therapy and is typically considered only after other strategies have failed, with regular reassessment of benefit, function, and risk.

• Other centrally acting pain-modulating medications

  Some medications primarily used for autonomic or neuropsychiatric indications may influence pain perception in select individuals with hypermobile Ehlers-Danlos syndrome.

  • Alpha-2 adrenergic agonists

    • Examples include clonidine and guanfacine

    • May reduce sympathetic overactivity and pain amplification in some patients

    • Risks include hypotension, sedation, and worsening orthostatic intolerance

  • Ketamine (specialist-directed)

    • Occasionally used in refractory centralized pain syndromes under specialist supervision

    • Evidence in hEDS is lacking

    • Potential risks include dissociation, cardiovascular effects, and neuropsychiatric symptoms

  These approaches are typically managed by pain specialists and are not routine treatments.

• Other medications sometimes encountered in pain management

  • Acetazolamide

    • Occasionally used in headache disorders associated with pressure-related symptoms.

    • May worsen fatigue, electrolyte imbalance, or orthostatic symptoms in susceptible individuals.

  • Bisphosphonates or bone-targeted therapies

    • Not analgesics themselves but may indirectly reduce pain in individuals with stress fractures, low bone density, or fracture-related pain.

    • Use requires careful assessment of bone health and long-term risk.

  These medications are used selectively and are not standard treatments for hEDS-related pain.

• Theoretical adjunct: Low-dose naltrexone (LDN) has shown promise in small studies. (See Medication Metabolization article below for information on LDN). Opioids should be limited to select cases with regular reassessment.

• Cannabidiol (CBD)

  • What it is

    • A non-intoxicating cannabinoid derived from hemp or cannabis.

    • Does not produce a “high.”

    • Available over-the-counter in many formulations (oral, topical, sublingual), and as a prescription medication (Epidiolex) for seizure disorders.

  • Evidence for pain

    • No clinical trials have evaluated CBD specifically for pain in hypermobile Ehlers-Danlos syndrome (hEDS).

    • Randomized trials in related chronic pain conditions (fibromyalgia, osteoarthritis, neuropathic pain) show that oral purified CBD alone does not consistently outperform placebo for pain relief or functional improvement.

    • Major clinical guidelines conclude that CBD monotherapy probably has little or no effect on chronic non-cancer pain.

    • Patient surveys in hEDS and related conditions report perceived benefit, but these studies cannot determine true effectiveness and often do not distinguish CBD from THC.

  • What patients sometimes report

    • Mild reduction in pain or muscle tension

    • Improved sleep or relaxation

    • Reduced anxiety (variable)

  • Safety considerations

    • Common side effects: diarrhea, fatigue, sedation, appetite or sleep changes.

    • Can interact with many medications through liver enzyme inhibition (CYP3A4, CYP2C19).

    • Over-the-counter products vary widely in purity and labeling accuracy; some contain THC or contaminants.

    • Long-term safety data for chronic use in pain populations are limited.

  • Bottom line

    • CBD has not been shown in controlled studies to reliably reduce chronic pain, including in hEDS.

    • Some individuals perceive benefit, but effectiveness remains unproven.

    • If used, careful attention to drug interactions and product quality is important.

      
      

• Tetrahydrocannabinol (THC)

  • What it is

    • The primary psychoactive cannabinoid in cannabis.

    • Produces intoxication and altered perception.

    • Legality varies by state (medical and/or recreational use).

  • Evidence for pain

    • Controlled trials in neuropathic pain and some chronic pain conditions show modest average pain reduction with THC-containing products.

    • No clinical trials have evaluated THC specifically in hEDS.

    • Benefits vary widely between individuals and are often limited by side effects.

    • THC may improve sleep more consistently than pain for some patients.

  • What patients sometimes report

    • Reduced pain or muscle tension

    • Improved sleep initiation

    • Appetite stimulation

    • Reduced nausea

    • Relaxation or mood change (can also worsen anxiety)

  • Risks and cautions

    • Dizziness, impaired balance, and fall risk

    • Worsening tachycardia or orthostatic symptoms (important in dysautonomia/POTS)

    • Cognitive impairment (attention, memory, reaction time)

    • Anxiety, panic, or paranoia in susceptible individuals

    • Interaction with sedating medications

    • Impaired driving and safety risks

    • Risk of dependence with regular use

  • Special populations requiring caution

    • Adolescents and young adults

    • History of psychosis or severe anxiety

    • Significant dysautonomia (problems with automatic body functions such as heart rate, blood pressure, temperature regulation, or digestion) or frequent syncope (fainting or passing out)

    • Polypharmacy (taking multiple prescription medications at the same time, increasing the risk of interactions) or patients using sedatives (medications that cause drowsiness, slowed thinking, or impaired coordination)

    • Pregnancy

  • Bottom line

    • THC may provide modest symptom relief for some individuals with chronic pain, but benefits are variable and risks are meaningful.

    • It is not disease-modifying and may worsen certain hEDS-related symptoms.

    • Use should be cautious, individualized, and discussed with a clinician.

Comparison Chart — CBD vs THC

Fatigue and Sleep Disturbance

Like pain, fatigue in hEDS is profound, disabling, rarely driven by a single cause, and often responds incompletely to medication alone. Contributing factors include pain, deconditioning, poor sleep, hormonal dysregulation, nutritional deficits, and autonomic dysfunction.

Fatigue in hEDS often overlaps with chronic pain, autonomic dysfunction, and central sensitization, making pharmacologic treatment challenging. Medications used to improve sleep or reduce pain may worsen daytime fatigue, orthostatic intolerance, or cognitive fog. As a result, medication strategies for fatigue are often conservative, trial-based, and combined with non-pharmacologic approaches, with close monitoring for trade-offs between nighttime symptom relief and daytime function.

• Supportive care: Physical therapy, energy conservation, and psychological strategies

• Underlying contributors: Treat pain, insomnia, anxiety, POTS, MCAS, and screen for thyroid/adrenal dysfunction

• Medications: Low-dose amitriptyline or trazodone may improve sleep and mood

• Modafinil: Sometimes used off-label, but may worsen insomnia or anxiety

• Endocrine testing is recommended for those with unexplained fatigue. The results of this testing may lead to medication options to treat fatigue (see below).

• Stimulants and Caffeine

The role of stimulants and caffeine in hEDS remains controversial due to overlap with existing symptoms.

• Prescription stimulants (e.g., methylphenidate, amphetamines, modafinil) may help in co-occurring ADHD but are not recommended for general fatigue due to risks of

  • Insomnia

  • Anxiety

  • Appetite suppression

  • Tachycardia and blood pressure elevation

  • Mood instability and rebound fatigue

• Caffeine is widely used.

  • Use may cause palpitations.

  • Use may worsen GI symptoms.

  • Use may worsen sleep disturbances.

  • Regular use can lead to tolerance and dependency.

• Stimulants may also disrupt hormone regulation, including suppression of cortisol (a key stress hormone) or interference with appetite-related hormones such as leptin and growth hormone—effects that may be especially problematic in people with hEDS due to their sensitivity to hormonal shifts and vulnerability to fatigue, weight fluctuation, and autonomic imbalance.

Headaches

Headaches in hEDS often reflect overlapping mechanisms rather than a single headache disorder. Recurrent headaches in hEDS are common and may be migraine, tension-type, or cervicogenic in origin.

• Abortive treatments: NSAIDs, acetaminophen, triptans

• Preventive medications: TCAs, SNRIs, anticonvulsants

• Other preventive options

  • Acetazolamide may be considered in select headache syndromes, particularly when features suggest altered cerebrospinal fluid dynamics.

  • Calcitonin gene-related peptide (CGRP)–targeting therapies, including monoclonal antibodies and small-molecule inhibitors, are increasingly used for migraine prevention. Evidence specific to hEDS is lacking, and tolerability varies.

• Medication selection should account for cervical instability, autonomic symptoms, medication sensitivity, and the risk of overuse or rebound headaches.

• Cervical instability-related: Gentle physical therapy, soft collars, postural adaptations

Headache care should account for the presence of cervical spine instability, medication overuse, and comorbid POTS or MCAS, which can exacerbate vascular headaches.

Psychiatric Symptoms

Mood and anxiety symptoms are common and may reflect chronic illness stress, trauma, medical invalidation, or neurodevelopmental overlap.

• Medications:

  • SSRIs (e.g., sertraline, fluoxetine)

  • SNRIs (e.g., duloxetine, venlafaxine)

  • TCAs (used cautiously due to anticholinergic and cardiovascular risks)

• ADHD and ASD: Treated per standard protocols

• Risks: Monitor for orthostatic hypotension, drug interactions, suicidality, and sedative burden

Adjunctive (add-on) therapy such as ACT, DBT, or trauma-informed psychotherapy is often essential for long-term mental health outcomes.

Autonomic Dysfunction and Mast Cell Activation

POTS (Postural Orthostatic Tachycardia Syndrome)

Many individuals with hEDS have co-occurring POTS, requiring specific medications to manage tachycardia, fatigue, and lightheadedness

• Beta-blockers (e.g., propranolol, atenolol)

• Fludrocortisone: Increases blood volume

• Midodrine: Alpha agonist to raise blood pressure

• Pyridostigmine: Improves autonomic tone

• Ivabradine (off-label): Selective heart rate control without lowering BP

These drugs require individualized titration and should be balanced with fluid intake, salt loading, and compression garments.

MCAS (Mast Cell Activation Syndrome)

MCAS affects a subset of patients with hEDS and requires careful medication management, often with attention to excipients and routes of administration

• H1 antihistamines: Cetirizine, fexofenadine

• H2 blockers: Famotidine, ranitidine (discontinued in some regions)

• Mast cell stabilizers: Cromolyn sodium (oral or nebulized)

• Leukotriene inhibitors: Montelukast

• Emergency medications: Epinephrine auto-injector for anaphylaxis

• Compounding: Dye-free, preservative-free formulations may be necessary

Medications that release histamine (e.g., opioids, some antibiotics) are often avoided when possible, particularly in individuals with known mast cell reactivity.

Gastrointestinal and Endocrine Considerations

Connective tissue dysfunction in the GI tract can lead to poor motility, reflux, constipation, and malabsorption of both nutrients and medications.

• Motility management: Prokinetic agents, osmotic laxatives, antispasmodics, dietary strategies (e.g., small meals, fiber modification)

• Reflux: PPIs, H2 blockers, sucralfate

• Malabsorption

  • Consider sublingual, transdermal, or injectable routes for essential meds (e.g., B12, iron)

  • Avoid relying solely on oral absorption when absorption is poor

Endocrine disorders may be overlooked or misattributed. Screen for:

• Thyroid dysfunction (hypothyroidism, subclinical hypothyroidism)

• Adrenal insufficiency

• Hormonal imbalance, especially in menstruating individuals or those with weight fluctuations

Nutritional Supplements

Due to dietary restrictions, GI dysfunction, or chronic inflammation, hEDS patients often have low levels of essential nutrients

• Common deficiencies: Iron, vitamin D, calcium, B12, folate

• Delivery routes

  • Oral when tolerated

  • Sublingual or parenteral (injections/IV) when malabsorption is present

• Protein supplementation: May aid recovery in underweight or deconditioned patients

Avoid megadoses or untargeted supplementation without lab confirmation. Some supplements may interact with medications (e.g., calcium and thyroid hormone).

Tissue and Medication-Specific Risks

Tissue Fragility

• Increased risk of bruising, hematoma, and skin tearing with injections or adhesive patches

• IM or SC injections may require smaller needles or alternative routes

• Vascular access may be more difficult; fragile veins prone to rupture

Medication Classes of Concern

• Fluoroquinolones: Risk of tendon rupture, especially in weight-bearing joints; generally avoided unless no reasonable alternatives exist

• Long-term corticosteroids: Accelerated bone loss, impaired wound healing

• PPIs: May reduce calcium and magnesium absorption, especially in long-term use

Hormonal Medications

• Oral contraceptives and HRT

  • May worsen migraines

  • Potential interaction with vascular instability

  • Consider non-oral or progestin-only methods in high-risk individuals

Other Considerations

OTC and Topical Agents

• Diphenhydramine: Anticholinergic burden, sedation, falls in older adults

• Pseudoephedrine: May worsen POTS symptoms

• Topical pain creams: Lidocaine, capsaicin, arnica, or menthol may aid focal pain

• Barrier creams or wound-healing ointments: Important for fragile skin

Polypharmacy and Safety Concerns

Polypharmacy means taking multiple prescription medications at the same time, increasing the risk of interactions. It often refers to people who are taking five or more medications.

Patients with hEDS are frequently prescribed multiple medications, raising the risk of interactions and adverse effects. Because people with hEDS often see multiple specialists, medication lists can grow quickly without a single provider overseeing interactions.

• Medication review: Reassess at every visit

• Deprescribing: Prioritize elimination of ineffective or harmful agents

• Monitoring:

  • Interactions (especially CNS depressants, serotonergic agents, and cardiovascular meds)

  • Fall risk

  • Nutrient-drug competition

Age-Specific Considerations

• Children: Use weight-based dosing; avoid growth-inhibiting medications

• Adults: Adjust for comorbidities and long-term side effects

• Older adults: Start low, go slow; avoid high-anticholinergic burden, benzodiazepines

Summary

Pain in hypermobile Ehlers-Danlos syndrome usually comes from several overlapping causes, including joint instability, muscle overuse, nerve-related pain, autonomic nervous system problems, poor sleep, and changes in how the nervous system processes pain. As a result, pain management often involves trialing multiple medication classes over time, frequently as adjuncts rather than standalone solutions. Responses to medications vary widely and are often limited by side effects, which is why non-medication approaches play an important role in long-term care for many people.

Differences in research strength across therapies should not be assumed to reflect how helpful a treatment may be for an individual, since many commonly used approaches in hEDS have simply not been well studied yet. Cannabis-based products require careful weighing of risks and benefits, especially for people with autonomic symptoms, frequent fainting, multiple medications, or balance and thinking concerns. Overall, pain management in hEDS works best when it is personalized and focused on safety, daily function, symptom pacing, and quality of life, recognizing that meaningful improvement does not require complete symptom elimination.

Medication Metabolization in hEDS

This section is more technical and is included for readers who want a deeper understanding of why medication responses can be unpredictable in hEDS.

Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of the Ehlers-Danlos syndromes, a group of heritable connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. It is a multisystem disorder with complex symptoms including chronic pain, gastrointestinal dysmotility, autonomic dysfunction, and frequent comorbidities like mast cell activation disorders (MCAD). Given the high symptom burden and frequent medication use, there is growing interest in whether hEDS patients metabolize medications differently or require unique approaches to pharmacologic management.

While high-quality pharmacokinetic (PK, how the body absorbs, distributes, metabolizes, and excretes drugs) and pharmacodynamic (PD, how the drug affects the body, including therapeutic effects and side effects) studies in hEDS are lacking, there are both theoretical and observational data suggesting that medication absorption, distribution, metabolism, and response may be atypical in this population. These considerations vary across age groups and medication classes and are further complicated by hEDS-associated conditions such as GI dysfunction, dysautonomia, and MCAD. This overview synthesizes current knowledge and identifies key gaps.

Theoretical Factors Affecting Medication Response in hEDS

Empirical Evidence for PK/PD Differences in hEDS

• Limited data available

  • No published studies directly measuring PK or PD differences in hEDS.

  • Most existing literature identifies the absence of data rather than documenting findings.

• Large cohort studies show higher medication usage in hEDS

  • Pediatric and adult EDS populations demonstrate higher rates of prescriptions, especially opioids and GI medications.

  • Example: Opioid use was double in children with EDS (27.5% vs. 13.5%) and higher in adults (62% vs. 34.1%).

• Reduced efficacy of local anesthetics

  • Common clinical finding in hEDS, especially in dental settings.

  • Mechanism unknown; may involve tissue permeability or vascularity.

Theoretical Mechanisms Impacting Medication Response

• Connective tissue abnormalities

  • ECM disarray may affect distribution, especially for injected or depot drugs.

• Gastrointestinal dysmotility (abnormal movement of the digestive tract)

  • Delayed gastric emptying, constipation, and reflux are common.

  • May lead to delayed or reduced oral medication absorption.

• Autonomic dysfunction

  • Alters circulation and organ perfusion.

  • May impact drug delivery and metabolism, especially in IV medications.

• Mast cell activation disorders (MCAD)

  • May cause allergic or non-IgE-mediated reactions to medications or additives.

• Enzyme variability

  • Some speculation exists around CYP450 pathway variation in hEDS, but no confirmation.

Medication Class-Specific Observations

Age-Specific Considerations

Impact of MCAD (Mast Cell Activation Disorder - Mast Cell Activation Syndrome is a subset of Mast Cell Activation Disorder) on Drug Response

• MCAD can lead to

  • Increased hypersensitivity reactions

  • Poor tolerance of excipients (fillers, dyes, preservatives)

• Treatment strategies include

  • Trigger avoidance (e.g., heat, stress, alcohol)

  • Antihistamines: H1 (e.g., cetirizine), H2 (e.g., famotidine)

  • Mast cell stabilizers (e.g., cromolyn sodium)

  • Escalation to biologics in refractory cases

Clinical Guidelines and Implications

• No current guidelines recommend specific hEDS-related dosing or medication protocols.

• Management is based on standard practices with individual titration based on tolerability and response.

• Multidisciplinary collaboration is encouraged, especially when managing pain, GI symptoms, and MCAD.

Summary

Although rigorous pharmacologic studies are lacking, theoretical mechanisms and observational trends support the need for individualized medication management in hEDS. Clinical experience shows altered responses, particularly to anesthetics and opioids, and patients often require lower starting doses, slower titration, or alternative formulations. Until better evidence is available, careful monitoring, symptom-based management, and multidisciplinary coordination remain best practices.

Low-Dose Naltrexone (LDN)

Low-dose naltrexone (LDN) is an emerging off-label option for people with widespread pain, fatigue, and central sensitization—features common in hEDS.

What is it?

• A very low dose (1.5–4.5 mg) of the drug naltrexone, traditionally used in much higher doses for opioid or alcohol dependence.

• In low doses, it works very differently, modulating pain and inflammation through unique mechanisms.

• Must be obtained at a compounding pharmacy.

• Often is not covered by insurance due to being prescribed off-label. Off-label prescribing is when a healthcare provider prescribes a medication for a use, dose, or population that is not specifically approved by the FDA but is supported by clinical judgment or evidence from research.

How might it help in hEDS?

• LDN is not a standard therapy for hEDS, but it is increasingly used off-label for chronic pain conditions involving central sensitization, such as fibromyalgia, which shares overlapping features with hEDS.

• Proposed mechanisms

  • Inhibition of microglial activation in the central nervous system

  • Toll-like receptor 4 (TLR4) antagonism

  • Reduction of neuroinflammation, possibly helping to dampen pain amplification and brain fog

• Patients often report improvements in

  • Chronic widespread pain

  • Fatigue

  • Sleep quality

  • Cognitive clarity

Evidence base

• Evidence for LDN in hEDS specifically is limited to anecdotal reports and clinician experience.

• However, systematic reviews and meta-analyses show modest benefit in fibromyalgia and related centralized pain conditions, with a good safety profile.

• Most published studies are small or preliminary; high-quality randomized controlled trials in hEDS are currently lacking.

Tolerability

• LDN is generally well-tolerated.

• May have mild and temporary side effects such as vivid dreams or sleep disruption early on.

Formulations

Because commercial manufacturers do not produce tablets in low doses, LDN must be specially prepared by compounding pharmacies. Common formulations include:

• Capsules – The most typical option, often filled with microcrystalline cellulose or another neutral filler. Available in precise strengths (e.g., 1.5 mg, 3 mg, 4.5 mg).

• Tablets – Less commonly compounded but sometimes preferred for patients who have trouble swallowing capsules.

• Liquid formulations – Useful for those who require very gradual dose titration (e.g., starting below 1 mg and increasing slowly). Allows for flexible adjustment in 0.1–0.5 mg increments.

• Sublingual drops or lozenges – Occasionally used when gastrointestinal absorption is a concern, though less standardized.

• Topical creams – An experimental option prepared by some pharmacies, typically for patients who cannot tolerate oral forms; evidence is minimal.

Because inactive ingredients vary between pharmacies, patients with sensitivities to dyes, fillers, or excipients (inactive ingredients) may need to request specific formulations. Prescribers can work with the compounding pharmacist to adjust both dosage and formulation to the patient’s needs.

Insurance and Prescription Access

• Insurance coverage is inconsistent. Many insurers consider LDN experimental or non-essential due to its off-label use and will not reimburse for compounded versions.

• Prior authorization or appeal letters from a provider may be required for coverage, and even then, success varies by plan.

• Compounding pharmacies are typically required because low-dose tablets are not commercially manufactured. Prices can range from $30–90/month depending on formulation and location.

• Patients should

  • Ask whether their prescriber can fax the prescription directly to a known compounding pharmacy.

  • Inquire about discount programs or bulk pricing through pharmacies.

  • Save receipts for out-of-pocket costs, which may be reimbursable through FSA/HSA accounts.

• Some patients also find better prices at online or mail-order compounding pharmacies, though quality and licensing should be verified.